Collegium Pharmaceutical, Inc. COLL Belbuca — Cost, Amortization
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSoldAmortization.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — cost, amortization of $18.85M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization decreased by 0.0% year-over-year, from $18.85M to $18.85M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization?
- Over 2 years (2023 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — cost, amortization has grown at a 0.0% compound annual growth rate (CAGR), from $75.39M to $75.4M.
- What does belbuca — cost, amortization mean?
- The periodic non-cash expense recognized to allocate the cost of Belbuca-related intangible assets over their estimated useful lives. This reflects the systematic reduction in the asset's book value as it contributes to revenue generation.